7 Sands Capital Ultragenyx Pharmaceutical Trades
Sands Capital acquired 4.3 Million Ultragenyx Pharmaceutical shares worth $155 Million. That's 0.46% of their equity portfolio (37th largest holding). The investor owns 4.19% of the outstanding Ultragenyx Pharmaceutical stock. The first Ultragenyx Pharmaceutical trade was made in Q2 2023. Since then Sands Capital bought shares two more times and sold shares on four occasions. The investor's estimated purchase price is $186 Million, resulting in a loss of 17%.
News about Ultragenyx Pharmaceutical Inc. and Sands Capital
Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Joshua Higa - Vice President of I...
Ultragenyx Pharmaceutical''s Return On Capital Employed Insights
Benzinga Pro data, Ultragenyx Pharmaceutical (NASDAQ: RARE ) reported Q1 sales of $100.50 million. Earnings fell to a loss of $163.97 million, resulting in a...
Rock Springs Capital Management LP Buys Baxter International Inc, Warby Parker Inc, Ultragenyx ...
Related Stocks: RARE , ASND , CERE , ACCD , SRRA , MGNX , BAX , WRBY , IMRX , ABOS , AADI , ICVX , BGNE , ARDX , BIIB , BSX , PPD , ADPT ,
Cinctive Capital Management LP Grows Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Cinctive Capital Management LP increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 92.0% during the 2nd quarter, according to...